A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
2023 · Nature Medicine · 213 citations
https://doi.org/10.1038/s41591-023-02234-6
A
Anita Schmitt
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
225
Papers
5.9K
Citations
41
h-index
113
i10-index
Anita Schmitt is an academic researcher from Heidelberg University. The author has contributed to research in topics: CAR-T cell therapy research & Immunotherapy and Immune Responses & Immune Cell Function and Interaction. The author has an h-index of 41, co-authored 192 publications.
Papers by this author
worksThird-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
2023 · Annals of the Rheumatic Diseases · 113 citations
https://doi.org/10.1136/ard-2023-225174
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
2022 · Nature Cancer · 62 citations
https://doi.org/10.1038/s43018-022-00503-w
Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients
2020 · Molecular Therapy — Methods & Clinical Development · 52 citations
https://doi.org/10.1016/j.omtm.2020.02.003
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
2024 · Leukemia · 34 citations
https://doi.org/10.1038/s41375-024-02392-7
Effects of nilotinib on regulatory T cells: the dose matters
2010 · Molecular Cancer · 29 citations
https://doi.org/10.1186/1476-4598-9-22
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat